Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
TRADOOR fluctuates by 152.2% within 24 hours: Speculative pump driven by whale activity and surging trading volume

TRADOOR fluctuates by 152.2% within 24 hours: Speculative pump driven by whale activity and surging trading volume

Bitget PulseBitget Pulse2026/04/11 02:10
Show original
By:Bitget Pulse

Volatility Overview

In the past 24 hours, TRADOOR's price surged from a low of $2.0814 to a high of $5.2499, currently quoted at $4.2256, with a price swing amplitude of 152.2%. Trading volume skyrocketed to approximately $64.3 million, a 134.62% increase compared to the previous period, with PancakeSwap V3 (BSC) accounting for 51.24% (about $33 million). The total liquidation in 24 hours reached $428,600, mainly with $132,800 from long positions and $295,800 from short positions.

Brief Analysis of the Price Movement Causes

- Whale activity and speculative pump: Bitget Pulse monitoring indicates that the movement was mainly driven by whale operations, with the price first plunging 56% within one hour before instantly pumping 160%, wiping out late short positions.

- Explosive trading volume: 24-hour trading volume surged 134% from prior levels, led by PancakeSwap, driving the price up from around $3.21 to $5.05 before partially retracing.

There were no official announcements or significant news events; the movement was purely driven by market speculation.

Market Sentiment and Outlook

The prevailing sentiment in the community is caution, with high volatility viewed as “abnormal” and seen as “bull/bear traps” risk. Traders complain about price instability (as Binance Square users commented, “too many unstable moves”). AI analysts (like Finora AI) suggest waiting for a pullback to confirm support at $4.37–4.35 for buying, avoiding chasing highs; if it breaks above the recent high of $4.86, the target is $5.13, otherwise a deeper correction to $4.07 is expected. Overall risk reminder: high leverage liquidations are frequent, and short-term volatility may continue.

Note: This analysis is automatically generated by AI based on public data and on-chain monitoring, and is for informational purposes only.
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

AI Sell-off Hits Anthropic IPO, Potential Valuation Expected to Drop to $1.2–1.3 Trillion

The valuation range discussed by potential investors has been lowered from the previous high of $2 trillion to between $1.2 trillion and $1.3 trillion, and some strategists have even suggested going below $1 trillion to ensure safety. In the face of significant market volatility and financial concerns such as quarterly losses, Anthropic is facing tough decisions, including a discounted valuation, reducing the size of the offering, or postponing the listing.

华尔街见闻•2026/11/06 13:42
AI Sell-off Hits Anthropic IPO, Potential Valuation Expected to Drop to $1.2–1.3 Trillion

Moderna Q3 revenue up 29% year-on-year, far exceeding expectations, raises full-year revenue growth guidance to 15%-25% | Earnings Report Insight

Moderna's Q3 revenue increased by 29% year-on-year to $1.31 billion, with profits significantly exceeding expectations. The company raised its 2026 revenue growth guidance to 15%-25%. The ramp-up of next-generation COVID-19 and flu vaccines, along with international market expansion, has driven performance improvement. Phase III data for the personalized cancer vaccine has also shown positive progress. The company is simultaneously advancing cost reduction and pipeline R&D, with year-end cash expectations significantly raised.

华尔街见闻•2026/11/06 13:23

Eli Lilly (LLY.US) "lowers its stance" and joins forces with former rival Hims (HIMS.US) to compete for the self-pay weight loss drug market

Eli Lilly is collaborating with Hims & Hers Health, leveraging the telehealth company’s large customer base to expand access to its blockbuster weight loss drugs and boost sales of medications, including its new oral weight loss drug Foundayo.

智通财经•2026/11/06 12:37
Eli Lilly (LLY.US) "lowers its stance" and joins forces with former rival Hims (HIMS.US) to compete for the self-pay weight loss drug market